Phibro Animal Health Corp Files 8-K on Officer/Director Changes
Ticker: PAHC · Form: 8-K · Filed: Dec 18, 2025 · CIK: 1069899
| Field | Detail |
|---|---|
| Company | Phibro Animal Health Corp (PAHC) |
| Form Type | 8-K |
| Filed Date | Dec 18, 2025 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
Related Tickers: PAHC
TL;DR
Phibro Animal Health Corp (PAHC) filed an 8-K detailing leadership changes and compensation arrangements.
AI Summary
Phibro Animal Health Corporation filed an 8-K on December 18, 2025, reporting on events that occurred on December 16, 2025. The filing covers the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements for certain officers. It also includes Regulation FD disclosures and financial statements with exhibits.
Why It Matters
This 8-K filing indicates potential shifts in the leadership and governance of Phibro Animal Health Corporation, which could impact strategic direction and investor confidence.
Risk Assessment
Risk Level: low — The filing is a standard 8-K reporting routine corporate governance and personnel matters, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- Phibro Animal Health Corporation (company) — Registrant
- December 18, 2025 (date) — Filing Date
- December 16, 2025 (date) — Earliest Event Date
FAQ
What specific officer or director positions were affected by the events reported in this 8-K?
The filing indicates changes related to the departure of directors or certain officers, election of directors, and appointment of certain officers, but the specific names and positions are not detailed in the provided excerpt.
Are there any details regarding the compensatory arrangements for the officers mentioned?
The filing lists 'Compensatory Arrangements of Certain Officers' as an item covered, but the specific details of these arrangements are not included in the provided text.
What is the significance of the 'Regulation FD Disclosure' mentioned in the filing?
Regulation FD (Fair Disclosure) ensures that material information is broadly disseminated to the public, preventing selective disclosure to analysts or institutional investors.
What type of financial statements or exhibits are included with this 8-K filing?
The filing states that 'Financial Statements and Exhibits' are included, but the specific content of these exhibits is not detailed in the provided excerpt.
When was Phibro Animal Health Corporation incorporated and in which state?
Phibro Animal Health Corporation was incorporated in Delaware.
Filing Stats: 908 words · 4 min read · ~3 pages · Grade level 11.2 · Accepted 2025-12-18 16:20:50
Key Financial Figures
- $0.0001 — hich registered Class A Common Stock, $0.0001 par value per share PAHC NASDAQ Sto
Filing Documents
- tm2533792d1_8k.htm (8-K) — 29KB
- tm2533792d1_ex99-1.htm (EX-99.1) — 11KB
- tm2533792d1_ex99-1img001.jpg (GRAPHIC) — 14KB
- 0001104659-25-122556.txt ( ) — 227KB
- pahc-20251216.xsd (EX-101.SCH) — 3KB
- pahc-20251216_lab.xml (EX-101.LAB) — 33KB
- pahc-20251216_pre.xml (EX-101.PRE) — 22KB
- tm2533792d1_8k_htm.xml (XML) — 4KB
02
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS. On December 18, 2025, Phibro Animal Health Corporation ("Phibro" or the "Company") announced that Jack C. Bendheim, the current Chairman of the Board of Directors of the Company (the "Board"), Chief Executive Officer and President, will resign from his position as Chief Executive Officer and President, effective July 1, 2026 (the "Effective Date"). On the Effective Date, Mr. Jack C. Bendheim will assume a new managerial role as Executive Chairman and will continue to support strategic oversight and work closely with the executive leadership team. Mr. Jack C. Bendheim will continue to serve as the Chairman of the Board of Directors of the Company. On the Effective Date, Daniel (Dani) Bendheim, age 53, the Company's current Executive Vice President, Corporate Strategy, will assume the role of Chief Executive Officer and President of the Company. Mr. Dani Bendheim brings approximately 28 years of knowledge of the Company's business into his new role, having first joined the Company in 1997. He was appointed the Company's Vice President of Business Development in 2001, appointed President, Performance Products in 2004, and then appointed to his current role as Executive Vice President, Corporate Strategy in March 2014. He was elected as member of the Board in November 2013. Mr. Dani Bendheim is the son of Mr. Jack C. Bendheim, and the brother of Mr. Jonathan Bendheim, a member of the Board, and, together with certain other family members, is a Manager of BFI Co., LLC ("BFI"), an investment vehicle of the Bendheim family, with respect to the economic rights pertaining to shares of Company stock owned by BFI. For a description of Mr. Dani Bendheim's family relationships with other directors and executive officers and for related party transactions, please see his biography under the heading "Executive Officers" and "Certain Relationships and Related Party
01
ITEM 7.01 REGULATION FD DISCLOSURE. On December 18, 2025, the Company issued a press release announcing Mr. Jack C Bendheim resigning from his role as Chief Executive Officer and President of the Company, and the appointment of Mr. Dani Bendheim as his successor to such roles, effective as of July 1, 2026. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01 and in the press release is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of, or otherwise regarded as filed under, the Securities Exchange Act of 1934, as amended (the "Exchange Act"), nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
FINANCIAL STATEMENTS AND EXHIBITS
FINANCIAL STATEMENTS AND EXHIBITS. (d) Exhibits Exhibit Number Description 99.1 Press Release, dated December 18, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. PHIBRO ANIMAL HEALTH CORPORATION Registrant Date: December 18, 2025 By: /s/ Judith Weinstein Name: Judith Weinstein Title: Senior Vice President, General Counsel and Corporate Secretary